title: [Rapamycin inhibits the proliferation of prostate cancer cell line 22RV1 and activity of S6K1].
abstract: OBJECTIVE
  To explore the effects of rapamycin on the proliferation of prostate cancer cell line 22RV1 and the activity of S6K1.
  
  
  METHODS
  Prostate cancer 22RV1 cells cultured in vitro were treated with rapamycin at the concentrations of 0, 50, 100, 200 and 400 nmol/L. The inhibition rate of the cells'proliferation was detected by MTT, and the activity of S6K1 was determined by liquid scintillation counting.
  
  
  RESULTS
  Rapamycin significantly inhibited the proliferation of the prostate cancer 22RV1 cells and the activity of S6K1 in a dose- dependent manner, most obviously at 400 nmol/L (P<0.01).
  
  
  CONCLUSIONS
  Rapamycin can effectively suppress the proliferation of prostate cancer 22RV1 cells by regulating the expression of S6K1, the downstream protein of mammalian target of rapamycin (mTOR).
authors.affiliation: Department of Urology, Nangang Branch of Heilongjaing Provincial Hospital, Harbin, Heilongjiang 150001, China.
authors.forename: Kai
authors.initials: K
authors.lastname: Liang
authors.forename: De-Xiang
authors.initials: DX
authors.lastname: Lu
authors.forename: Ning
authors.initials: N
authors.lastname: Chu
authors.forename: Jie
authors.initials: J
authors.lastname: Cheng
mesh_terms: D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D006801:Humans; D008297:Male; D011467:Prostate / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D038762:Ribosomal Protein S6 Kinases, 70-kDa / Q000378:metabolism*; D020123:Sirolimus / Q000494:pharmacology*
chemical_list: D038762:Ribosomal Protein S6 Kinases, 70-kDa; C448901:ribosomal protein S6 kinase, 70kD, polypeptide 1; D020123:Sirolimus